Biomoda Files Additional Patent Protection for Its Lung Cancer Detection Technology
Biomoda, Inc., maker of patented early lung cancer detection testing and other cancer diagnostic technology, confirmed today that it is continuing to expand its patent portfolio with a unique patent pending for the use of its patented porphyrin molecule to detect different cell variations of lung cancer. “It is important that the Company protect all the various uses of this molecule, setting up a barrier to entry for competition,” said John Cousins, President of Biomoda. “We are protecting the value of our core patents with patents that detail improvements and new uses of our strong, innovative technology. This prevents those on the periphery from attempting to target our patents with a so-called ‘picket fence’ of minor patents that could weaken our powerful market position.”
This entry was posted on Tuesday, May 29th, 2007 at 10:16 am and is filed under Research, Early Detection. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.